Clinical trial NCT01579474: Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial
Official title: Safety, Efficacy and Pharmacokinetics of BI 201335 NA in Patient With Genotype 1 Chronic Hepatitis C Virus Infection in Combination With Pegylated Interferon Alfa-2b and Ribavirin - Cohort 1 for Treatment-naive Patients: Randomised, Double-blind Part of BI 201335 NA for 12 or 24 Weeks - Cohort 2 for Treatment-experienced Patients: Open-label Part of BI 201335 NA for 24 Weeks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hepatitis C
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2012-04-18
Enrollment: 131
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this trial is to evaluate the safety and efficacy of BI 201335 given for 12 or 24 weeks in combination with PegIFN alfa-2b/RBV given for 24 or 48 weeks in chronic genotype 1 hepatitis C virus infected treatment-naïve and treatment-experienced Japanese patients


Eligibility criteria: Inclusion criteria:

1. Chronic hepatitis C infection, diagnosed by positive anti-HCV antibodies and detected HCV RNA at screening in addition to:

   * positive anti-HCV antibodies or detected HCV RNA at least 6 months before screening; or,
   * liver biopsy consistent with chronic HCV infection.
2. HCV genotype 1 infection confirmed by genotypic testing at screening
3. (For Cohort 1 only) Therapy-naïve to interferon, pegylated interferon, and ribavirin (For Cohort 2 only) Confirmed prior virological failure (null response, partial response, breakthrough or relapse) with an approved dose of PegIFN alfa/RBV or IFN beta/RBV for at least 12 weeks and with an 8-week washout period before screening
4. HCV RNA = 100,000 IU/mL at screening
5. Documentation of a liver biopsy within 3 years or fibroscan within 6 months before randomization (Visit 2)
6. Age 20 to 70 years
7. Female patients who are infertile or who are of childbearing potential with a negative pregnancy test and agreeing to use one accepted method of birth control in addition to the use of a condom by their male partners.

   or Male patients who are infertile, who are without pregnant female partners or who consistently and correctly use condoms.
8. Signed informed consent form before trial participation

Exclusion criteria:

1. HCV infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening,
2. Evidence of acute or chronic liver disease due to causes other than chronic HCV infection. Steatosis diagnosed incidentally (e.g. by biopsy) without clinical relevance is not an exclusion criterion.
3. HIV co-infection,
4. Hepatitis B virus (HBV) infection based on presence of hepatitis B surface antigen (HBsAg),
5. Active malignancy, or history of malignancy within the last 5 years prior to screening (with an exception of appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix),
6. Active or, history of alcohol or illicit drug abuse within the past 12 months,
7. A condition that is defined as one which in the opinion of investigator may put the patient at risk because of participation in this study, may influence the results of this study, or limit the patient's ability to participate in this study,
8. Usage of any investigational drugs within 30 days prior to screening, or planned usage of an investigational drug during the course of this study,
9. Received concomitant systemic antiviral, hematopoietic growth factor, or immunomodulatory treatment within 30 days prior to screening. Patients being treated with oral antivirals such as acyclovir, famciclovir or valacyclovir for recurrent herpes simplex infection; or with oseltamivir or zanamivir for influenza A infection, may be screened,
10. Received silymarin (milk thistle), glycyrrhizin (Stronger Neo-Minophagen C; SNMC), or Sho-saiko-to (SST) within 28 days prior to randomization (Visit 2) and throughout the treatment phase of this trial,
11. (For Cohort 2 only) Patients who have been previously treated with at least one dose of any antiviral or immunomodulatory drug other than (pegylated) interferon alfa, interferon beta or ribavirin for acute or chronic HCV infection including and not restricted to protease or polymerase inhibitors,
12. Known hypersensitivity to any ingredient of the study drugs,
13. Alpha fetoprotein value \>100 ng/mL at screening; if \>20 ng/mL and =100 ng/mL, patients may be included if there is no evidence of liver cancer in an appropriate imaging study (e.g., ultrasound, CT scan, or MRI) within last 6 months prior to randomization (Visit 2),

Other exclusion criteria related to pegylated interferon and/or ribavirin restrictions are not listed here.

Primary outcomes:
measure: Number of Patients With Investigator Defined Drug-related Adverse Events
timeFrame: Up to 52 weeks
Secondary outcomes:
measure: Sustained Virological Response (SVR12), Defined as Plasma HCV RNA Undetectable at 12 Weeks After End of Treatment (EOT)
timeFrame: EOT (up to Week 24 or 48) and 12 weeks after the EOT (up to Week 36 or 60)
measure: Sustained Virological Response (SVR24), Defined as Plasma HCV RNA Undetectable at 24 Weeks After End of Treatment (EOT)
timeFrame: EOT (up to Week 24 or 48) and 24 weeks after the EOT (up to Week 48 or 72)
measure: Early Treatment Success (ETS), Defined as Plasma HCV RNA <25 IU/mL at Week 4 and HCV RNA Undetectable at Week 8
timeFrame: up to 8 weeks
measure: Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12=YES
timeFrame: EOT (up to Week 24 or 48)
measure: Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12= NO
timeFrame: EOT (up to Week 24 or 48)
measure: Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=YES
timeFrame: 12 weeks after the EOT (up to Week 36 or 60)
measure: Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=NO
timeFrame: 12 weeks after the EOT (up to Week 36 or 60)
measure: Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=YES
timeFrame: EOT (up to Week 24 or 48)
measure: Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=NO
timeFrame: EOT (up to Week 24 or 48)
measure: Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=YES
timeFrame: 12 weeks after the EOT (up to Week 36 or 60)
measure: Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=NO
timeFrame: 12 weeks after the EOT (up to Week 36 or 60)
Other outcomes:
Locations:
city: Chuo-ku, Chiba
country: Japan
facility: 1220.54.08104 Boehringer Ingelheim Investigational Site
city: Chuo-ku, Kobe, Hyogo
country: Japan
facility: 1220.54.08118 Boehringer Ingelheim Investigational Site
city: Fukui, Fukui
country: Japan
facility: 1220.54.08108 Boehringer Ingelheim Investigational Site
city: Gifu, Gifu
country: Japan
facility: 1220.54.08110 Boehringer Ingelheim Investigational Site
city: Itabashi-ku, Tokyo
country: Japan
facility: 1220.54.08105 Boehringer Ingelheim Investigational Site
city: Izunokuni, Shizuoka
country: Japan
facility: 1220.54.08112 Boehringer Ingelheim Investigational Site
city: Kanazawa, Ishikawa
country: Japan
facility: 1220.54.08107 Boehringer Ingelheim Investigational Site
city: Kita-gun, Kagawa
country: Japan
facility: 1220.54.08120 Boehringer Ingelheim Investigational Site
city: Kofu, Yamanashi
country: Japan
facility: 1220.54.08109 Boehringer Ingelheim Investigational Site
city: Kurume, Fukuoka
country: Japan
facility: 1220.54.08123 Boehringer Ingelheim Investigational Site
city: Mtsuyama, Ehime
country: Japan
facility: 1220.54.08121 Boehringer Ingelheim Investigational Site
city: Nagoya, Aichi
country: Japan
facility: 1220.54.08113 Boehringer Ingelheim Investigational Site
city: Nishinomiya, Hyogo
country: Japan
facility: 1220.54.08117 Boehringer Ingelheim Investigational Site
city: Ogaki, Gifu
country: Japan
facility: 1220.54.08111 Boehringer Ingelheim Investigational Site
city: Oo mura, Nagasaki,
country: Japan
facility: 1220.54.08124 Boehringer Ingelheim Investigational Site
city: Osaka, Osaka
country: Japan
facility: 1220.54.08115 Boehringer Ingelheim Investigational Site
city: Osakasayama, Osaka
country: Japan
facility: 1220.54.08116 Boehringer Ingelheim Investigational Site
city: Sapporo, Hokkaido
country: Japan
facility: 1220.54.08101 Boehringer Ingelheim Investigational Site
city: Sendai, Miyagi
country: Japan
facility: 1220.54.08102 Boehringer Ingelheim Investigational Site
city: Tanabe, Wakayama
country: Japan
facility: 1220.54.08119 Boehringer Ingelheim Investigational Site
city: Toyama,Toyama
country: Japan
facility: 1220.54.08106 Boehringer Ingelheim Investigational Site
city: Tsu, Mie
country: Japan
facility: 1220.54.08114 Boehringer Ingelheim Investigational Site
city: Yahatanishi-ku, Kitakyusyu, Fukuoka
country: Japan
facility: 1220.54.08122 Boehringer Ingelheim Investigational Site
city: Yamagata, Yamagata
country: Japan
facility: 1220.54.08125 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Nishiguchi S, Urano Y, Suzaki K, Taniguchi A, Scherer J, Berger KL, Quinson AM, Stern JO, Omata M. Safety and efficacy of faldaprevir in combination with pegylated interferon alpha-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection. Hepatol Res. 2017 Mar;47(3):E142-E151. doi: 10.1111/hepr.12741. Epub 2016 Aug 10.